145 related articles for article (PubMed ID: 15470958)
1. Circadian rhythm of irinotecan tolerability in mice.
Filipski E; Lemaigre G; Liu XH; Méry-Mignard D; Mahjoubi M; Lévi F
Chronobiol Int; 2004 Jul; 21(4-5):613-30. PubMed ID: 15470958
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel chronopharmacology in mice.
Tampellini M; Filipski E; Liu XH; Lemaigre G; Li XM; Vrignaud P; François E; Bissery MC; Lévi F
Cancer Res; 1998 Sep; 58(17):3896-904. PubMed ID: 9731500
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice.
Ohdo S; Makinosumi T; Ishizaki T; Yukawa E; Higuchi S; Nakano S; Ogawa N
J Pharmacol Exp Ther; 1997 Dec; 283(3):1383-8. PubMed ID: 9400014
[TBL] [Abstract][Full Text] [Related]
4. Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics.
Lévi F; Tampellini M; Metzger G; Bizi E; Lemaigre G; Hallek M
Int J Cancer; 1994 Nov; 59(4):543-7. PubMed ID: 7960225
[TBL] [Abstract][Full Text] [Related]
5. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
Granda TG; Filipski E; D'Attino RM; Vrignaud P; Anjo A; Bissery MC; Lévi F
Cancer Res; 2001 Mar; 61(5):1996-2001. PubMed ID: 11280758
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice.
Li XM; Vincenti M; Lévi F
Chronobiol Int; 2002 Jan; 19(1):43-55. PubMed ID: 11962685
[TBL] [Abstract][Full Text] [Related]
7. Circadian rhythm in toxic effects of cystemustine in mice: relevance for chronomodulated delivery.
Martineau-Pivoteau N; Levi F; Rolhion C; Kwiatkowski F; Lemaigre G; Filipski E; Chollet P
Int J Cancer; 1996 Nov; 68(5):669-74. PubMed ID: 8938151
[TBL] [Abstract][Full Text] [Related]
8. Circadian pharmacology of L-alanosine (SDX-102) in mice.
Li XM; Kanekal S; Crépin D; Guettier C; Carrière J; Elliott G; Lévi F
Mol Cancer Ther; 2006 Feb; 5(2):337-46. PubMed ID: 16505107
[TBL] [Abstract][Full Text] [Related]
9. Sex and dosing-time dependencies in irinotecan-induced circadian disruption.
Ahowesso C; Li XM; Zampera S; Peteri-Brunbäck B; Dulong S; Beau J; Hossard V; Filipski E; Delaunay F; Claustrat B; Lévi F
Chronobiol Int; 2011 May; 28(5):458-70. PubMed ID: 21721861
[TBL] [Abstract][Full Text] [Related]
10. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice.
Filipski E; Amat S; Lemaigre G; Vincenti M; Breillout F; Lévi FA
J Pharmacol Exp Ther; 1999 Apr; 289(1):231-5. PubMed ID: 10087009
[TBL] [Abstract][Full Text] [Related]
11. Circadian-time dependent tolerance and haematological toxicity to isoniazid in murine.
Souayed N; Chennoufi M; Boughattas F; Hassine M; Ben Attia M; Aouam K; Reinberg A; Boughattas NA
Biomed Pharmacother; 2015 Apr; 71():233-9. PubMed ID: 25960242
[TBL] [Abstract][Full Text] [Related]
12. Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.
Filipski E; Berland E; Ozturk N; Guettier C; van der Horst GT; Lévi F; Okyar A
Toxicol Appl Pharmacol; 2014 Feb; 274(3):471-9. PubMed ID: 24380837
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
14. Circadian rhythm in tolerance of mice for the new anthracycline analog 4'-O-tetrahydropyranyl-adriamycin (THP).
Levi F; Mechkouri M; Roulon A; Bailleul F; Lemaigre G; Reinberg A; Mathe G
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1245-51. PubMed ID: 4076288
[TBL] [Abstract][Full Text] [Related]
15. Circadian variation of isoniazid pharmacokinetics in mice.
Souayed N; Chennoufi M; Frej NB; Chaabane A; Ben-Attia M; Aouam K; Reinberg A; Boughattas NA
Biomed Pharmacother; 2016 Dec; 84():1150-1155. PubMed ID: 27780145
[TBL] [Abstract][Full Text] [Related]
16. Cell kinetics-dependent antitumor effect of irinotecan hydrochloride induced by the synchronizing effect of hydroxyurea: cell kinetics and dosing time.
Akagi T; Ushinohama K; Kage Y; Ishizaki T; Makinosumi T; Yamauchi A; Taguchi Y; Inoue K; Yukawa E; Higuchi S; Ohdo S
Life Sci; 2003 Jan; 72(10):1183-97. PubMed ID: 12505548
[TBL] [Abstract][Full Text] [Related]
17. Radiation enhancement by 9-aminocamptothecin: the effect of fractionation and timing of administration.
Kirichenko AV; Rich TA
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):659-64. PubMed ID: 10348297
[TBL] [Abstract][Full Text] [Related]
18. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma.
Granda TG; D'Attino RM; Filipski E; Vrignaud P; Garufi C; Terzoli E; Bissery MC; Lévi F
Br J Cancer; 2002 Mar; 86(6):999-1005. PubMed ID: 11953836
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Hwang JJ; Marshall JL; Rizvi N
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):46-51. PubMed ID: 12800607
[TBL] [Abstract][Full Text] [Related]
20. Murine chronotoxicity to the antiallergic agent, cetirizine.
Dridi D; Mansour HB; Boughattas NA
Drug Chem Toxicol; 2011 Apr; 34(2):139-45. PubMed ID: 20586657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
